Skip to main content
Contact Us
Subscribe
E-Edition
80°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
March 05, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
March 03, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
February 20, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
February 18, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
February 05, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
January 21, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
January 13, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
January 06, 2025
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
December 19, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
December 12, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
December 04, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
November 11, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
November 06, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
October 24, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
September 23, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
September 09, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
September 04, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
August 26, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
August 09, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
August 07, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
August 06, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
June 28, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
May 09, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
April 30, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ASX:CSL
CSLLY
SPRY
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
April 03, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
March 07, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
March 06, 2024
From
ARS Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SPRY
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.